演題番号 : P19-5
- 演者）風間 慶祐:1,2
- 塩澤 学:1、内山 護:1、加藤 綾:1、佐藤 純人:1、菅野 伸洋:1、大島 貴:1、利野 靖:2、益田 宗孝:2
A Phase III study abroad has shown FOLFIRI + Ramucirumab (Rmab) to be effective as a second-line therapy for unresectable and recurrent colorectal cancer. However, there are many points that have not been fully studied yet, such as the effectiveness of those when using other than doublet (LOHP)+Bmab as the primary treatment. We will report on the outcomes using this regimen at Kanagawa Cancer Center. A single institute retrospective analysis of All 27 patients who underwent FOLFIRI + Rmab as a second-line treatment from July 2016 to March 2018. Patient background; Age 63 years (35-81), 13 males. Tumor localization was 6 cases of right side colon, 21 cases of left side colon or rectum. RAS wild type was 6 cases. We confirmed double heterozygosity for UGT1A1 gene polymorphism in 2 cases. PS; 0/1/2 = 9/15/3 cases. The median of CEA 19.8 ng/ml (1.5 - 2033), CA 19-9 57.8 ng / ml (2.0 - 17142). The number of metastatic organs:1/2 / ≧ 3 = 11/11/5 cases. The primary treatment: triplet + Bmab / doublet (LOHP) + Bmab / doublet (CPT11) + Bmab / doublet (LOHP) + Panitumumab (Pmab) / doublet (CPT11) +Pmab = 6/17/1/2/1 cases. Safety: The observed Adverse Event (AE) of Grade 3 or higher is as follows; neutropenia13cases (48.1%), pyrogenic neutropenia 3 (11.1%), leukopenia 7(25.9%), proteinuria 4(14.8%), dietary insomnia 4(14.8%), general fatigue 3 (11.1%), stomatitis 1(3.7%), and bleeding 1case (3.7%). Efficacy: The best overall response was CR / PR / SD / PD / NE = 0/3/16/5/3 cases. The median progression-free survival was 135 days. 135 days for Doublet (LOHP) + Bmab group, and 83 days for triplet + Bmab group. Differences in efficacy and safety were observed compared with Phase III trials for patients who received doublet (LOHP) + Bmab as the primary treatment. It is possible that the primary treatment regimen will affect on the efficacy and safety of FOLFIRI + Rmab. Tracking the overall survival time is necessary.